Is there a vaccine for hand foot and mouth disease?

Three inactivated vaccines targeting enterovirus A71 (EV-A71), the virus strain most likely to cause severe and fatal hand, foot, and mouth disease, have been licensed and administered in China since 2016. No country outside China has approved an HFMD vaccine, and no vaccine available anywhere protects against all the viruses that cause the illness. That gap matters because HFMD is triggered by more than a dozen related enteroviruses, and the strains circulating most widely have been shifting since the EV-A71 vaccines rolled out.

What Causes HFMD and Why One Vaccine Is Not Enough

Hand, foot, and mouth disease is not caused by a single virus. It is caused by a family of enteroviruses, with two historically dominant culprits: enterovirus A71 (EV-A71) and coxsackievirus A16 (CVA16). But epidemiological surveillance consistently finds a broader cast. A molecular study of HFMD specimens in Shanghai identified EV-A71 in about 64% of cases, CVA10 in 9%, CVA6 in 8%, and CVA16 in 7%, with smaller contributions from CVA12, CVA4, and others.¹ Studies across India have documented an even wider range, including coxsackieviruses A4 through A10, several B serotypes, and multiple echoviruses linked to both sporadic infections and outbreaks.²

The reason EV-A71 drew the most urgent vaccine attention is severity. Most HFMD is mild and resolves on its own, but EV-A71 is an outlier. In a large prospective hospital study, 40% of EV-A71 cases involved central nervous system complications, compared to just 4% for CVA16. EV-A71 also led to significantly more ICU admissions and longer hospital stays than every other serotype tested.³ Among hospitalized children in another study, all five fatalities occurred in the EV-A71 group, and EV-A71 was the strain most likely to cause brainstem encephalitis, neurogenic pulmonary edema, and coma.⁴ Outbreaks driven by EV-A71, particularly in children under five, have been linked to rapid death from complications including shock and pulmonary hemorrhage.⁵

So the current vaccines were designed to address the most dangerous strain. That was a rational starting point. But a vaccine against EV-A71 alone cannot prevent most HFMD cases, because the other serotypes keep circulating.

How Well the Existing EV-A71 Vaccines Work

Three Chinese manufacturers each developed an inactivated whole-virus EV-A71 vaccine, and all three went through phase III clinical trials before receiving approval. The trial results were strong. In one pivotal trial of over 10,000 children, vaccine efficacy against EV-A71-associated HFMD or herpangina was about 95%. Among vaccinated children, there were zero hospitalizations and zero cases with neurological complications during the surveillance period, compared to 24 hospitalizations and 8 neurological cases in the placebo group.⁶ A recent meta-analysis pooling five phase III trials with over 36,000 children found that vaccine efficacy against EV-A71-associated HFMD exceeded 98%.⁷

Real-world data from Shanghai spanning 2009 to 2023 backs this up. Among children who received both doses, effectiveness against EV-A71-associated outpatient visits was about 92%, against non-severe hospitalization about 88%, and against severe complications 100%.⁸ Children who received only one dose had considerably lower protection, around 68%, reinforcing that the two-dose series is important.

A modeling study has estimated how long protection lasts. It predicts about 80% efficacy at one month post-vaccination, declining to roughly 73% by year 20, with children who mount a strong initial immune response holding up better over time.⁹ That gradual decline is typical for inactivated vaccines and suggests that the protection, while not lifelong in its peak form, remains meaningful for many years.

The Strain Replacement Problem

Here is the catch that keeps infectious disease researchers busy: when you suppress one virus strain with a vaccine, related strains can fill the ecological gap. This is exactly what has been observed in China since EV-A71 vaccination began in 2016. The proportion of EV-A71 among detected HFMD pathogens dropped dramatically, from 28% in the pre-vaccine era to under 1% in recent surveillance periods in some regions.¹⁰ Meanwhile, CVA6 and CVA10 have emerged as the predominant circulating strains.¹¹

Longitudinal data from southern China confirms the pattern: CVA16 and CVA6 increased in proportion after the vaccination campaign, and researchers now hypothesize these strains have the potential to replace EV-A71 as the dominant players.¹² The overall HFMD incidence has declined since 2018, and severe and fatal cases have dropped substantially. That is a real public health win. But total case counts have not disappeared, because the non-EV-A71 viruses continue to circulate and cause mild-to-moderate disease, and in some cases, complications of their own. CVA4, for instance, caused neurological disease at a higher rate than CVA16 in one hospital-based study.³

In practical terms, getting your child vaccinated with the EV-A71 vaccine in China substantially reduces their risk of the most dangerous form of HFMD. But it will not prevent them from catching HFMD caused by other serotypes.

Multivalent Vaccines in Development

Researchers recognized the strain replacement problem early, and multiple labs have been working on vaccines that cover two, four, or even more serotypes. None have reached human licensure yet, but the preclinical results are promising.

Bivalent vaccines combining EV-A71 and CVA16 are the nearest horizon. In mouse studies, bivalent inactivated vaccines have produced strong antibody responses against both viruses and protected animals against lethal doses of each.¹³ Another bivalent candidate targeting EV-A71 and CVA16 triggered immune responses across multiple arms of the immune system, including T-cell activation, and significantly reduced paralysis and death in animal challenge experiments.¹⁴

Broader still, a tetravalent vaccine combining virus-like particles (VLPs) for EV-A71, CVA16, CVA10, and CVA6 produced neutralizing antibody levels comparable to each monovalent vaccine on its own. In animal tests, serum from mice immunized with the tetravalent vaccine protected against single or mixed infections with all four viruses, something no monovalent vaccine could do.¹⁵ A separate bivalent vaccine targeting CVA6 and CVA10 specifically showed over 80% protection in neonatal mice and passed antibodies effectively from vaccinated mothers to offspring.¹⁶

There is also interest in mRNA-based approaches. One group has developed CVA6 mRNA vaccines that not only induced strong T-cell immunity against CVA6 but also showed cross-protection against CVA10 infection in mice, a finding the researchers describe as the first trial of a CVA6 mRNA vaccine worldwide.¹⁷ Separately, an NIH-funded project is developing mosaic mRNA vaccines designed for broad coverage across multiple enterovirus A serotypes simultaneously.¹⁸

All of this is still preclinical or early-stage. Jumping from successful mouse studies to a licensed human vaccine typically takes years. But the pipeline is active and diverse, and the direction is clearly toward broader coverage.

Why You Cannot Get the Vaccine Outside China

The EV-A71 vaccines were developed, trialed, and approved exclusively in China. They are not licensed by the US FDA, the European Medicines Agency, or any other major regulatory body outside China. The reasons are partly commercial and partly epidemiological. HFMD is a particularly severe burden in the Asia-Pacific region, where large outbreaks involving thousands of children have driven urgent public health investment.¹⁹ In North America and Europe, HFMD certainly occurs, but large-scale fatal outbreaks driven by EV-A71 have been rarer, and the economic and political incentive to fast-track a vaccine has been lower.

Even within China, the EV-A71 vaccine is not part of the standard national immunization program in most areas. It is classified as a “non-program” (Category 2) vaccine, meaning parents pay out of pocket. This affects uptake. Cost-effectiveness analyses have concluded that including EV-A71 vaccination in routine childhood schedules would be cost-saving or highly cost-effective given the burden of severe disease in children under five.²⁰ When bivalent vaccines covering both EV-A71 and CVA16 become available, modeling suggests they could also be cost-effective compared to monovalent vaccines if priced appropriately.²¹

For parents outside of China, the practical answer right now is that no HFMD vaccine is available. There are no approved antiviral drugs for the illness either. Research into therapeutic monoclonal antibodies against CVA16 has shown promise in animal models but remains experimental.²² Similarly, antiviral peptides against EV-A71 have been investigated in preclinical studies but have not advanced to approved therapy.²³

Timing and the Window of Vulnerability

Babies are born with some protection against enteroviruses through antibodies passed from their mothers. But this shield fades fast. A longitudinal study of Chinese infants found that by six months of age, fewer than 7% still carried protective antibody levels against EV-A71, and a similar fraction had protective levels against CVA16.²⁴ A separate study found that maternal antibodies against CVA16 lasted fewer than three months on average, though infants born to mothers with higher antibody levels retained protection out to about six months.²⁵

This creates a window of vulnerability starting in the first few months of life, well before many vaccine schedules kick in. The Chinese EV-A71 vaccines are approved for children six months and older. Researchers have argued the optimal vaccination window against CVA16, when a vaccine becomes available, would be between about 1.5 months and one year of age, to cover that gap before natural infections become common in daycare and preschool settings.

What Parents Can Do Now

Without a broadly available vaccine, prevention still comes down to hygiene and outbreak management. A systematic review of control measures in childcare facilities found that timely implementation of infection control responses reduced both the number of cases and the duration of outbreaks.²⁶ The practical measures are familiar: keeping sick children home, cleaning frequently touched surfaces, and good hand hygiene after diaper changes and before meals.

The evidence on specific hygiene practices is less straightforward than you might expect. A case-control study in Singapore found that frequent hand washing with soap, for either children or adults, did not show a statistically significant protective effect against HFMD after adjusting for confounders. Nor did playing in indoor playgrounds or with neighborhood children increase risk significantly. Interestingly, infrequent toy cleaning (once every two to three weeks) was associated with slightly higher risk compared to never cleaning toys, possibly reflecting a false sense of security from sporadic cleaning that does not actually reduce viral load effectively.²⁷ The takeaway is not that hand washing is useless, but rather that enteroviruses spread so easily through oral and fecal routes that no single hygiene behavior in isolation provides strong protection. Consistency across multiple measures matters more than any one habit.

Parent Attitudes Toward the Existing Vaccine

Even where the EV-A71 vaccine is available, uptake is uneven. Surveys of Chinese parents tell a complicated story. In rural areas of Jiangsu Province, about 88% of parents said they were willing to vaccinate their children, with willingness higher among parents who understood the vaccine and perceived their child as susceptible to HFMD.²⁸ But in Guangzhou, a major city, only about 44% of parents expressed willingness, with the biggest barriers being fear of side effects and doubts about efficacy.²⁹

A survey in Chongqing found that about 28% of parents had already vaccinated their children, another 27% were willing after receiving information about the vaccine, and about 45% declined. Among those who declined, over half cited safety concerns, nearly half questioned the vaccine’s effectiveness, and roughly 38% doubted whether vaccination was even necessary.³⁰ The pattern is familiar from other vaccines: awareness and perceived risk drive acceptance, while the out-of-pocket cost of a non-program vaccine and unfamiliarity with a relatively new product hold it back.

Diagnosing Which Virus Is Responsible

One underappreciated piece of the puzzle is that doctors cannot tell which enterovirus is causing a given HFMD case just by looking at the child. The rash and fever look similar regardless of the serotype behind them. This matters for vaccine evaluation and public health surveillance, because you need laboratory testing to know whether the circulating viruses are the ones covered by the vaccine. Multiplex PCR assays have been developed that can simultaneously detect the four most common HFMD-causing enteroviruses (CVA6, CVA10, CVA16, and EV-A71) from a single clinical sample, providing results quickly enough to inform outbreak response and track whether strain replacement is happening in a given region.³¹ As multivalent vaccines eventually move toward approval, this kind of strain-level surveillance will become even more important to measure whether a broader vaccine is actually working as intended in the real world.